Core Viewpoint - The company successfully acquired a 40% stake in Huaxi Kangshengda, enhancing its strategic position in the southwestern region of China and aligning with its overall business strategy [1] Group 1: Acquisition Details - Wuhan Kangshengda has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will strengthen the company's management over Huaxi Kangshengda's operations and strategic direction, ensuring efficient and consistent execution of the overall strategy in the southwestern region [1] Group 3: Operational Enhancements - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergies between ICL-driven IVD product development and IVD service upgrades [1] - The company will take full control of Huaxi Kangshengda's management appointments, performance assessments, and resource allocation, enhancing the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the southwestern region to strengthen regional integrated operational capabilities [1]
康圣环球(09960)：武汉康圣达拟1239.6万元收购华西康圣达40%股权